🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 105 of 116

  1. ST1968

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  2. STP705

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  3. STRO-001

    SUTRO BIOPHARMA, INC.

    B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  4. STRO-002

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    2 trials

  5. STRO-004

    SUTRO BIOPHARMA, INC.

    Head and Neck Squamous Cell Carcinoma HNSCC

    phase 1 small molecule active

    1 trial

  6. SZ011 CAR-NK

    The First People's Hospital of Lianyungang

    Advanced Triple Negative Breast Cancer

    phase 1 small molecule active

    1 trial

  7. Safety and Early Signs of Efficacy of IL12-L19L19

    Philogen S.p.A.

    Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy

    phase 1 other active

    1 trial

  8. Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM

    Disc Medicine

    Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM)

    phase 1 other active

    1 trial

  9. Sapropterin dihydrochloride tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  10. Satraplatin in combo with vinorelbine

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  11. Selinexor

    Karyopharm Therapeutics Inc

    Prolymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  12. Selinexor

    Karyopharm Therapeutics Inc

    Colorectal Neoplasm

    phase 1 small molecule terminated

    1 trial

  13. Selinexor

    Karyopharm Therapeutics Inc

    Liposarcoma

    phase 1 small molecule terminated

    1 trial

  14. Selinexor

    Karyopharm Therapeutics Inc

    Soft Tissue Sarcoma

    phase 1 small molecule completed

    1 trial

  15. Selinexor

    Karyopharm Therapeutics Inc

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  16. Selinexor Pill

    Karyopharm Therapeutics Inc

    Hepatocellular Carcinoma

    phase 1 small molecule terminated

    1 trial

  17. Serine（Oral）

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 1 small molecule active

    1 trial

  18. Single FT1050 treated UCB unit

    Zafatek

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab completed

    1 trial

  19. Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  20. Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.

    Fondazione Telethon ETS

    Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry

    phase 1 other active

    1 trial

  21. Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer

    Eli Lilly Co.

    Lung Cancer or Breast Cancer

    phase 1 other active

    1 trial

  22. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  23. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  24. Study of GS-5319 in Adults With Solid Tumors

    Gilead Sciences Pty Limited

    Advanced solid tumors

    phase 1 other active

    1 trial

  25. Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Janssen-Cilag International N.V.

    Acute myeloid leukemia or Myelodysplastic syndrome

    phase 1 other active

    1 trial

  26. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  27. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  28. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  29. Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  30. Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  31. Study of U3-1402 in subjects with non-small cell lung cancer

    Daiichi Sankyo

    METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

    phase 1 other active

    1 trial

  32. Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

    Genmab A/S

    Advanced solid tumors

    phase 1 other active

    1 trial

  33. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  34. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  35. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  36. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  37. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  38. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  39. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  40. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  41. Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 other active

    1 trial

  42. Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  43. Sunitinib, Pemetrexed

    Pfizer

    Neoplasm, Malignant

    phase 1 small molecule completed

    1 trial

  44. Sup19 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  45. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  46. TAEST16001

    Chongqing Precision Biotech Co., Ltd

    Liver Cancer Stage IV

    phase 1 small molecule completed

    1 trial

  47. TAEST16001 cells

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  48. TAK-102

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.